ReviewInternational journal of molecular sciences2016
Epigenetic Modifications of Major Depressive Disorder.
Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 122 citations in OpenAlex.
- Differentially expressed microRNAs in human depression: a systematic review of case-control and longitudinal studies.BMC psychiatry · 2025Pooled it
- The Epigenetic Overlap between Obesity and Mood Disorders: A Systematic Review.International journal of molecular sciences · 2020Pooled it
- Dysregulation of the TLR4/MyD88/NF-κB Signaling Pathway and Pro-Inflammatory Cytokines in First-Episode Major Depressive Disorder: A Cross-Sectional Case-Control Study.Immunity, inflammation and disease · 2026Article
- Aberrant MicroRNA-124 expression and methylation in the dorsolateral prefrontal cortex of depressed subjects.Journal of psychiatric research · 2026Article
- Rewriting the brain: m6A RNA methylation as an emerging epitranscriptomic regulator in major depressive disorder.Frontiers in molecular neuroscience · 2026Review
- Multi-Omics Advances in Major Depressive Disorder for Molecular Insights, Biomarker Discovery, and Therapeutic Development.Aging and disease · 2025Review
- Impact of air pollution and occupational inhalation exposures on neurodegenerative disorders: An epigenetic perspective.iScience · 2025Review
- Epigenetic Modifications and Neuroplasticity in the Pathogenesis of Depression: A Focus on Early Life Stress.Behavioral sciences (Basel, Switzerland) · 2024Review
- Review
- Integrating mitoepigenetics into research in mood disorders: a state-of-the-art review.Frontiers in physiology · 2024Review
- Antidepressant and Anxiolytic Effects of L-Methionine in the WAG/Rij Rat Model of Depression Comorbid with Absence Epilepsy.International journal of molecular sciences · 2023Article
- Mitochondrial DNA oxidation, methylation, and copy number alterations in major and bipolar depression.Frontiers in psychiatry · 2023Article
- Research on Xiaoyao Powder in the treatment of depression based on epigenetics and quality markers.Frontiers in neuroscience · 2023Review
- DNA Methylation in Depression and Depressive-Like Phenotype: Biomarker or Target of Pharmacological Intervention?Current neuropharmacology · 2022Review
- Epigenetic and Neuronal Activity Markers Suggest the Recruitment of the Prefrontal Cortex and Hippocampus in the Three-Hit Model of Depression in Male PACAP Heterozygous Mice.International journal of molecular sciences · 2022Article
- RPS6KA5 methylation predict response to 6-week treatment for adolescent MDD patients.BMC psychiatry · 2022Article
- Genetic and epigenetic factors associated with depression: An updated overview.Saudi journal of biological sciences · 2022Review
- Major Depressive Disorder: Existing Hypotheses about Pathophysiological Mechanisms and New Genetic Findings.Genes · 2022Review
- Synergic action of L-acetylcarnitine and L-methylfolate in Mouse Models of Stress-Related Disorders and Human iPSC-Derived Dopaminergic Neurons.Frontiers in pharmacology · 2022Article
- Uncovering the Roles of MicroRNAs in Major Depressive Disorder: From Candidate Diagnostic Biomarkers to Treatment Response Indicators.Life (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) is a chronic disease whose neurological basis and pathophysiology remain poorly understood. Initially, it was proposed that genetic variations were responsible for the development of this disease. Nevertheless, several studies within the last decade have provided evidence suggesting that environmental factors play an important role in MDD pathophysiology. Alterations in epigenetics mechanism, such as DNA methylation, histone modification and microRNA expression could favor MDD advance in response to stressful experiences and environmental factors. The aim of this review is to describe genetic alterations, and particularly altered epigenetic mechanisms, that could be determinants for MDD progress, and how these alterations may arise as useful screening, diagnosis and treatment monitoring biomarkers of depressive disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.